Tolley 2024 summer team building event
The 2024 annual summer team building event saw the Tolley team attempt to sail the high seas by hiring a barge on the Peak District Canal! The whole team got involved with either steering, keeping us away from the edges, or operating the bridges. The weather could have been a bit kinder at times, but […]
Peak District Ultra Challenge 2024
So a big thanks to colleagues, associates and friends who sponsored and supported me on the Peak District ultra challenge last weekend. I managed to complete 100km walking continuously in 23 hours 22 mins. There was quite a lot of carnage along the way with strewn bodies and flagging legs from 70k but the support […]
Disappointing news for sickle cell disease community as Oxbryta (voxelotor) is withdrawn from global markets
Disappointing news for the sickle cell disease community; the benefits of Oxbryta (voxelotor) were determined to not outweigh the risks of the treatment and Pfizer have now pulled Oxbryta from markets globally. This is especially discouraging following the revoking of marketing authorisation of Adakveo (crizanlizumab) for sickle cell disease last year. After some work in […]
What will EU JCA mean for UK HTA?
As we support our global clients to prepare for the upcoming introduction of Joint Clinical Assessment (JCA) in the European Union (EU), the Tolley team have been devoting time to engaging in internal discussions on the knowns and unknowns of JCA. While the procedures and requirements for JCA have been made much clearer during 2024 […]
Health technology appraisal of gene and cell therapies for rare diseases
A rare disease is one that affects fewer than 1 in 2,000 people,[1] yet, since there are between 6,000 and 8,000 different rare diseases,[2, 3] they are collectively estimated to affect 1 in 17 people in the UK, at some point in their lives.[1] Around 80% of rare diseases have a genetic cause, and 70% […]
Case health technology
One-and-done HST success for the rare and painful skin condition, epidermolysis bullosa (EB) Read more
nice-home-dummy
NICE recommend… …the first therapy to treat epidermolysis bullosa (EB) Read more
Case health economic
Development of the first HTA-ready cost-effectiveness model for epidermolysis bullosa (EB) Read more
nice-home2 – Copy
Publication of the SLR and NMA for a non-statin, lipid-lowering therapy for patients with hypercholesterolaemia following successful reimbursement through NICE Read more
nice-home2
NICE recommend… …the first therapy to treat epidermolysis bullosa (EB) Read more